Publication

SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in <i>KRAS</i> G12C-mutant advanced NSCLC

Nishio, M.
; 
Negrao, M. V.
; 
Arbour, K. C.
; 
Burns, T. F.
; 
Cappuzzo, F.
; 
Dingemans, A. M. C.
; 
Girard, N.
; 
Gronberg, B. H.
; 
Hochmair, M.
; 
Leal, T.
... show 10 more
Citations
Altmetric:
Abstract
Neuroendocrine neoplasms of different origins, parathyroid carcinoma and intrathyroid thymic neoplasms are included.
Authors
Nishio, M.
Negrao, M. V.
Arbour, K. C.
Burns, T. F.
Cappuzzo, F.
Dingemans, A. M. C.
Girard, N.
Gronberg, B. H.
Hochmair, M.
Leal, T.
Lindsay, Colin R
Lu, S.
Paz-Ares, L. G.
Reck, M.
Sabari, J. K.
Spira, A. I.
William, W. N., Jr.
Chen, A.
Grul, C. M. V.
Peters, S.
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom
Description
Date
2024
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Nishio M, Negrao MV, Arbour KC, Burns TF, Cappuzzo F, Dingemans AMC, et al. SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in <i>KRAS</i> G12C-mutant advanced NSCLC. JOURNAL OF CLINICAL ONCOLOGY. 2024 AUG 10;42(23_SUPPL):TPS218-TPS. PubMed PMID: WOS:001346520000008. English.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/627406
Embedded videos